Angiotensin receptor neprilysin inhibitor for patients with heart failure and reduced ejection fraction: Real-world experience from Turkey (ARNi-TR).

Autor:	Ekici B; Department of Cardiology, Ufuk University School of Medicine, Ankara, Turkey., Yaman M; Department of Cardiology, Private Echomar Hospital, Zonguldak, Turkey., Küçük M; Department of Cardiology, Akdeniz University School of Medicine, Antalya, Turkey., Dereli S; Departmant of Cardiology, Ordu University School of Medicine, Ordu, Turkey., Yenerçağ M; Department of Cardiology, University of Health Sciences Samsun Training and Research Hospital, Samsun, Turkey., Yiğit Z; Institute of Cardiology, İstanbul University School of Medicine, İstanbul, Turkey., Baş MM; Department of Cardiology, Private Meydan Hospital, Şanlıurfa, Turkey., Karavelioğlu Y; Department of Cardiology, Hitit University School of Medicine, Çorum, Turkey., Çakmak HA; Department of Cardiology, Mustafakemalpaşa State Hospital, Bursa, Turkey., Kıvrak T; Department of Cardiology, Fırat University School of Medicine, Elazığ, Turkey., Özkan H; Department of Cardiology, VM Medical Park Bursa Hospital, Bursa, Turkey., Altın C; Department of Cardiology, Başkent University İzmir Zübeyde Hanım Application and Research Center, İzmir, Turkey., Şabanoğlu C; Department of Cardiology, Kırıkkale High Specialization Hospital, Kırıkkale, Turkey., Demirkan B; Department of Cardiology, Ankara City Hospital, Ankara, Turkey., Ataş AE; Department of Cardiology, VM Medical Park Samsun Hospital, Samsun, Turkey., Kılıçaslan F; Department of Cardiology, Bağcılar Medipol Mega University Hospital, İstanbul, Turkey., Altay H; Department of Cardiology, Başkent University School of Medicine, İstanbul, Turkey., Tengiz İ; Department of Cardiology, Medical Park İzmir Hospital, İzmir, Turkey., Fahri Erkan A; Department of Cardiology, Ufuk University School of Medicine, Ankara, Turkey., Kılıçaslan B; Department of Cardiology, University of Health Sciences, İzmir Tepecik Training and Research Hospital, Samsun, Turkey., Olgun FE; Department of Cardiology, Sefaköy Medipol University Hospital, İstanbul, Turkey., Durakoğlugil ME; Department of Cardiology, Recep Tayyip Erdoğan University School of Medicine, Rize, Turkey., Alhan A; Department of Biostatistics, Ufuk University School of Medicine, Ankara, Turkey., Zoghi M; Department of Cardiology, Ege University School of Medicine, İzmir, Turkey.
Jazyk:	angličtina
Zdroj:	Turk Kardiyoloji Dernegi arsivi : Turk Kardiyoloji Derneginin yayin organidir [Turk Kardiyol Dern Ars] 2021 Jul; Vol. 49 (5), pp. 357-367.
DOI:	10.5543/tkda.2021.63099
Abstrakt:	Objective: Heart failure (HF) is a growing public health problem with high morbidity and mortality. Recently, angiotensin receptor neprilysin inhibitor (ARNi) has emerged as a promising treatment for HF with reduced ejection fraction (HFrEF). Here, we shared our experience with the use of ARNi in HFrEF from multiple centers in Turkey. Methods: The ARNi-TR is a multicenter, noninterventional, retrospective, observational study. Overall, 779 patients with HF from 22 centers in Turkey who were prescribed sacubitril/valsartan were examined. Initial clinical status, biochemical and echocardiographic parameters, and New York Heart Association functional class (NYHA-FC) values were compared with follow-up values after 1 year of ARNi use. In addition, the effect of ARNi on number of annual hospitalizations was investigated, and the patients were divided into 2 groups, depending on whether ARNi was initiated at hospitalization or under outpatient clinic control. Results: N-terminal pro-brain natriuretic peptide (NT-proBNP), left-ventricle ejection fraction (LV-EF), and NYHA-FC values improved significantly in both groups (all parameters, p<0.001) within 1-year follow-up. In both groups, a decrease in hemoglobin A1c (HbA1c) values was observed in ARNi use (p<0.001), and a decrease in daily diuretic doses and hospitalizations owing to HF were observed after ARNi use (all comparisons, p<0.001). Hypotension (16.9%) was the most common side effect in patients using ARN. Conclusion: The ARNi-TR study offers comprehensive real-life data for patients using ARNi in Turkey. The use of ARNi has shown significant improvements in FC, NT-proBNP, HbA1c levels, and LV-EF. Likewise, reductions in the number of annual hospitalizations and daily furosemide doses for HF were seen in this study.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu